Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, Uber, Spok Holdings and Willis Lease Finance
by Zacks Equity Research
Microsoft, Novo Nordisk, Uber, Spok Holdings and Willis Lease Finance are included in this Analyst Blog.
Top Research Reports for Microsoft, Novo Nordisk & Uber
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Novo Nordisk A/S (NVO) and Uber Technologies, Inc. (UBER), as well as two micro-cap stocks Spok Holdings, Inc. (SPOK) and Willis Lease Finance Corp. (WLFC).
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
by Zacks Equity Research
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly
by Zacks Equity Research
Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
by Andrew Rocco
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
by Kinjel Shah
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
by Kinjel Shah
Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
by Zacks Equity Research
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?
by Shaun Pruitt
As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
by Zacks Equity Research
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day
Eli Lilly: The Next $1 Trillion Market Cap Stock?
by Ethan Feller
Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning
Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Company News for Aug 8, 2024
by Zacks Equity Research
Companies In The Article Are:SHOP, SUN, CIM,NVO
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look
by Derek Lewis
Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.
Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.